I. Grønlund B, Lundvall L, Christensen IJ, Knudsen JB, Hogdall C. Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel-platinum. Eur J Surg Oncol 2005; 31(1): 67-73.
II. Grønlund B, Hogdall C, Hansen HH, Engelholm SA. Results of reinduction therapy with paclitaxel and carboplatin in re-current epithelial ovarian cancer. Gynecologic Oncology 2001; 83(1): 128-34.
III. Grønlund B, Hansen HH, Hogdall C, Engelholm SA. Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma. CANCER 2002; 95(8):
1656-62.
IV. Grønlund B, Engelholm SA, Horvath G, Mäenpää J, Ridder-heim M. Sequential topotecan and oral etoposide in recurrent ovarian carcinoma pretreated with platinum-taxane. Results from a multicenter phase I/II study. CANCER 2005; 103(7):
1388-96.
V. Grønlund B, Hogdall C, Hansen HH, Engelholm SA. Per-formance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovar-ian carcinoma. CANCER 2002; 94(7): 1961-67
VI. Grønlund B, Hogdall C, Christensen IJ, Engelholm SA, Hansen HH. Is stabilization of disease a useful indicator for survival in second-line treatment of ovarian carcinoma pre-treated with paclitaxel-platinum? Gynecologic Oncology 2004; 94(2): 409-15.
VII. Grønlund B, Hansen HH, Hogdall C, Hogdall EV, Engelholm SA. Do CA125 response criteria overestimate tumour re-sponse in second-line treatment of epithelial ovarian carci-noma? Br J Cancer 2004; 90(2); 377-82.
VIII. Grønlund B, Hogdall C, Hilden J, Engelholm SA, Hogdall EVS, Hansen HH. Should CA-125 response criteria be pre-ferred to response evaluation criteria in solid tumors (RE-CIST) for prognostication during second-line chemotherapy of ovarian carcinoma? J Clin Oncol 2004; 22(20): 4051-58.
IX. Grønlund B, Dehn H, Hogdall C, Engelholm SA, Jørgensen M, Nørgaard-Pedersen B, Hogdall EVS. Cancer-associated _serum antigen (CASA) level: a novel prognostic indicator for survival in patients with recurrent ovarian carcinoma. Int J Gynecol Cancer 2005; 15 (5): 836-43.
X. Grønlund B, Christensen IJ, Bülow-Lehnsby AL, Engelholm SA, Hansen HH, Hogdall C. Recurrent epithelial ovarian can-cer: validation and improvement of an established prognostic index. Eur J Obstet Gyn Rep Biol 2005; 123 (1): 98-106.
The publications are referred to in the text by their Roman nu-merals.
REFERENCES
1. Histological typing of ovarian tumours. Scully, R. E. 1999. Geneva, World Health Organization.
2. Cancer facts and figures 2004. 2004. Atlanta, American Cancer Society.
3. Cancer incidence in Denmark 2000. 2004. Sundhedsstyrelsen (National Board of Health).
4. Anderson JR, Cain KC, and Gelber RD: Analysis of survival by tumor response. J Clin Oncol 1: 710-719, 1983.
5. Aravantinos G, Dimopoulos MA, Kosmidis P, Bafaloukos D, Papadimi-triou C, Kiamouris C, Pavlidis N, Sikiotis K, Papakostas P, and Skarlos DV: Ifosfamide plus oral etoposide salvage chemotherapy for platinum-resistant paclitaxel-pretreated ovarian cancer. Ann Oncol 11: 607-612, 2000.
6. Armstrong DK: Topotecan dosing guidelines in ovarian cancer: reduc-tion and management of hematologic toxicity. Oncologist 9: 33-42, 2004.
7. Avall-Lundqvist E, Nordstrom L, Sjovall K, and Eneroth P: Evaluation of seven different tumour markers for the establishment of tumour marker panels in gynecologic malignancies. Eur J Gynaecol Oncol 10:
395-405, 1989.
8. Baak JP, Langley FA, Talerman A, and Delemarre JF: The prognostic variability of ovarian tumor grading by different pathologists. Gynecol Oncol 27: 166-172, 1987.
9. Balducci L and Extermann M: Cancer chemotherapy in the older pa-tient: what the medical oncologist needs to know. Cancer 80: 1317-1322, 1997.
10. Bast RC, Jr., Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR, Jr., and Knapp RC: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309: 883-887, 1983.
11. Beato CV: A health message: when it comes to hypertension, we need your help. J Natl Med Assoc 96: 1105-1106, 2004.
12. Benedet JL, Bender H, Jones H, III, Ngan HY, and Pecorelli S: FIGO staging classifications and clinical practice guidelines in the manage-ment of gynecologic cancers. FIGO Committee on Gynecologic Oncol-ogy. Int J Gynaecol Obstet 70: 209-262, 2000.
13. Berek JS, Bertelsen K, du BA, Brady MF, Carmichael J, Eisenhauer EA, Gore M, Grenman S, Hamilton TC, Hansen SW, Harper PG, Horvath G, Kaye SB, Luck HJ, Lund B, McGuire WP, Neijt JP, Ozols RF, Parmar MK, Piccart-Gebhart MJ, van Rijswijk R, Rosenberg P, Rustin GJ, Sessa C, and Willemse PH: Advanced epithelial ovarian cancer: 1998 consen-sus statements. Ann Oncol 10 Suppl 1: 87-92, 1999.
14. Berek JS, Trope C, and Vergote I: Surgery during chemotherapy and at relapse of ovarian cancer. Ann Oncol 10 Suppl 1: 3-7, 1999.
15. Bertelsen K: Tumor reduction surgery and long-term survival in ad-vanced ovarian cancer: a DACOVA study. Gynecol Oncol 38: 203-209, 1990.
16. Bertelsen K, Holund B, and Andersen E: Reproducibility and prognostic value of histologic type and grade in early epithelial ovarian cancer. Int J Gynecol Cancer 3: 72-79, 1993.
17. Bicher A, Sarosy G, Kohn E, Adamo DO, Davis P, Jacob J, Chabner BA, and Reed E: Age does not influence taxol dose intensity in recurrent car-cinoma of the ovary. Cancer 71: 594-600, 1993.
18. Blackledge G, Lawton F, Redman C, and Kelly K: Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for pa-tient treatment and the design of phase II trials. Br J Cancer 59: 650-653, 1989.
19. Blessing JA: Design, analysis and interpretation of chemotherapy trials in gynecologic cancer. In: Chemotherapy of gynecologic cancer (Deppe G ed). New York, Wiley, 1990, pp 63-97.
20. Bokkel HW, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, Broom C, Scarabelli C, Davidson N, Spanczynski M, Bolis G, Malm-strom H, Coleman R, Fields SC, and Heron JF: Topotecan versus pacli-taxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15: 2183-2193, 1997.
21. Bolis G, Parazzini F, Scarfone G, Villa A, Amoroso M, Rabaiotti E, Po-latti A, Reina S, and Pirletti E: Paclitaxel vs epidoxorubicin plus pacli-taxel as second-line therapy for platinum-refractory and -resistant ovarian cancer. Gynecol Oncol 72: 60-64, 1999.
22. Bolis G, Scarfone G, Giardina G, Villa A, Mangili G, Melpignano M, Presti M, Tateo S, Franchi M, and Parazzini F: Carboplatin alone vs car-boplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer. Gynecol Oncol 81: 3-9, 2001.
23. Bomalaski JJ: The treatment of recurrent ovarian carcinoma: balancing patient desires, therapeutic benefit, cost containment and quality of life.
Curr Opin Obstet Gynecol 11: 11-15, 1999.
24. Bookman MA, Malmstrom H, Bolis G, Gordon A, Lissoni A, Krebs JB, and Fields SZ: Topotecan for the treatment of advanced epithelial ovar-ian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 16: 3345-3352, 1998.
25. Bosze P, Bast RC, Berchuck A, Burke HB, Buller RE, Creasman WT, Dubeau L, Fox H, Geisler HE, Geisler JP, Henson DE, Rustin GJ, Ver-morken JB, Wells M, and Wilbanks GD: Conseusus statements on prog-nostic factors in epithelial ovarian carcinoma. Report of the Consensus Meeting organized by the European Society of Gynaecological Oncol-ogy, ESGO. Eur J Gynaecol Oncol 21: 513-526, 2000.
26. Bridgewater JA, Nelstrop AE, Rustin GJ, Gore ME, McGuire WP, and Hoskins WJ: Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclit-axel. J Clin Oncol 17: 501-508, 1999.
27. Bristow RE, Simpkins F, Pannu HK, Fishman EK, and Montz FJ: Posi-tron emission tomography for detecting clinically occult surgically re-sectable metastatic ovarian cancer. Gynecol Oncol 85: 196-200, 2002.
28. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, and Montz FJ:
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20:
1248-1259, 2002.
29. Buda A, Floriani I, Rossi R, Colombo N, Torri V, Conte PF, Fossati R, Ravaioli A, and Mangioni C: Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the Mario Negri In-stitute, Milan, G.O.N.O. (Gruppo Oncologico Nord Ovest) group and I.O.R. (Istituto Oncologico Romagnolo) group. Br J Cancer 90: 2112-2117, 2004.
30. Buyse M and Piedbois P: On the relationship between response to treat-ment and survival time. Stat Med 15: 2797-2812, 1996.
31. Calvert AH, Newell DR, Gumbrell LA, O’Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, and Wiltshaw E: Carboplatin dosage:
prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748-1756, 1989.
32. Campos SM, Penson RT, Mays AR, Berkowitz RS, Fuller AF, Goodman A, Matulonis UA, Muzikansky A, and Seiden MV: The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. Gynecol Oncol 81:
206-212, 2001.
33. Cannistra SA: Is there a “best” choice of second-line agent in the
treat-ment of recurrent, potentially platinum-sensitive ovarian cancer? J Clin Oncol 20: 1158-1160, 2002.
34. Cannistra SA: Progress in the management of gynecologic cancer: con-census summary statement. J Clin Oncol 21: 129-132, 2003.
35. Cannistra SA: Cancer of the ovary. N Engl J Med 351: 2519-2529, 2004.
36. Cantu MG, Buda A, Parma G, Rossi R, Floriani I, Bonazzi C, Dell’Anna T, Torri V, and Colombo N: Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in pa-tients with recurrent ovarian cancer who responded to first-line plati-num-based regimens. J Clin Oncol 20: 1232-1237, 2002.
37. Cesano A, Lane SR, Poulin R, Ross G, and Fields SZ: Stabilization of dis-ease as a useful predictor of survival following second-line chemother-apy in small cell lung cancer and ovarian cancer patients. Int J Oncol 15:
1233-1238, 1999.
38. Chen LM and Karlan BY: Recurrent ovarian carcinoma: is there a place for surgery? Semin Surg Oncol 19: 62-68, 2000.
39. Clemmensen I, Petersen LC, and Kluft C: Purification and characteriza-tion of a novel, oligomeric, plasminogen kringle 4 binding protein from human plasma: tetranectin. Eur J Biochem 156: 327-333, 1986.
40. Colombo N, Parma G, Bocciolone L, Sideri M, Franchi D, and Mag-gioni A: Role of chemotherapy in relapsed ovarian cancer. Crit Rev On-col Hematol 32: 221-228, 1999.
41. Cormio G, di Vagno G, Cazzolla A, Bettocchi S, di Gesu G, Loverro G, and Selvaggi L: Surgical treatment of recurrent ovarian cancer: report of 21 cases and a review of the literature. Eur J Obstet Gynecol Reprod Biol 86: 185-188, 1999.
42. Cornelison TL and Reed E: Dose intensity analysis of high-dose carbo-platin in refractory ovarian carcinoma relative to age. Cancer 71: 650-655, 1993.
43. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, and Skriver L: Plasminogen activators, tissue degradation, and cancer.
Adv Cancer Res 44: 139-266, 1985.
44. Davelaar EM, Bonfrer JM, Verstraeten RA, Bokkel Huinink WW, and Kenemans P: CA 125: a valid marker in ovarian carcinoma patients treated with paclitaxel? Cancer 78: 118-127, 1996.
45. de Jong RS, Hofstra LS, Willemse PH, de Bruijn HW, de Vries EG, Boonstra H, and Mulder NH: Effect of low-dose oral etoposide on serum CA-125 in patients with advanced epithelial ovarian cancer.
Gynecol Oncol 66: 197-201, 1997.
46. Dehn H.: Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer. Acta Obstet Gynecol Scand 82: 1-7, 2003.
47. Deng X, Hogdall EV, Hogdall CK, Norgaard-Pedersen B, Jorgensen M, Nielsen H, and Engelholm SA: The prognostic value of pretherapeutic tetranectin and CA-125 in patients with relapse of ovarian cancer.
Gynecol Oncol 79: 416-419, 2000.
48. Dent SF and Eisenhauer EA: Phase I trial design: are new methodologies being put into practice? Ann Oncol 7: 561-566, 1996.
49. Deppe G and Baumann P: Advances in ovarian cancer chemotherapy.
Current Opinion in Oncology 12: 481-491, 2000.
50. Devine PL, McGuckin MA, Quin RJ, and Ward BG: Predictive value of the combination of serum markers, CA125, CASA and TPS in ovarian cancer. Int J Gynecol Cancer 5: 170-178, 1995.
51. Dieras V, Bougnoux P, Petit T, Chollet P, Beuzeboc P, Borel C, Husseini F, Goupil A, Kerbrat P, Misset JL, Bensmaine MA, Tabah-Fisch I, and Pouillart P: Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients.
Ann Oncol 13: 258-266, 2002.
52. Dizon DS, Hensley ML, Poynor EA, Sabbatini P, Aghajanian C, Hum-mer A, Venkatraman E, and Spriggs DR: Retrospective analysis of car-boplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. J Clin Oncol 20: 1238-1247, 2002.
53. du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, Bauknecht T, Richter B, Warm M, Schroder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, and Pfisterer J: A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95: 1320-1329, 2003.
54. du Bois A, Meier W, Luck HJ, Emon G, Moebus V, Schroeder W, Costa S, Bauknecht T, Olbricht S, Jackisch C, Richter B, and Wagner U:
Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsge-meinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer. Ann Oncol 251-257, 2002.
55. Duffy MJ: Clinical uses of tumor markers: a critical review. Crit Rev Clin Lab Sci 38: 225-262, 2001.
56. Eisenhauer EA, Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg ME, Kerr I, Vermorken JB, Buser K, and Colombo N:
European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 12: 2654-2666, 1994.
57. Eisenhauer EA, Gore M, and Neijt JP: Ovarian cancer: should we be
managing patients with good and bad prognostic factors in the same manner? Ann Oncol 10 Suppl 1: 9-15, 1999.
58. Eisenkop SM, Friedman RL, and Spirtos NM: The role of secondary cytoreductive surgery in the treatment of patients with recurrent epi-thelial ovarian carcinoma. Cancer 88: 144-153, 2000.
59. Eisenkop SM, Nalick RH, and Teng NN: Modified posterior exenter-ation for ovarian cancer. Obstet Gynecol 78: 879-885, 1991.
60. Fleming TR and DeMets DL: Surrogate end points in clinical trials: are we being misled? Ann Intern Med 125: 605-613, 1996.
61. Frasci G, Conforti S, Zullo F, Mastrantonio P, Comella G, Comella P, Persico G, and Iaffaioli RV: A risk model for ovarian carcinoma patients using CA 125: time to normalization renders second-look laparotomy redundant. Cancer 77: 1122-1130, 1996.
62. Funt SA, Hricak H, Abu-Rustum N, Mazumdar M, Felderman H, and Chi DS: Role of CT in the management of recurrent ovarian cancer. AJR Am J Roentgenol 182: 393-398, 2004.
63. Gadducci A, Iacconi P, Cosio S, Fanucchi A, Cristofani R, and Riccardo GA: Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. Gynecol Oncol 79:344-349, 2000.
64. Gadducci A, Landoni F, Maggino T, Sartori E, Zola P, Ferdeghini M, Parma G, and Cristofani R: Serum CA125 assay at the time of relapse has no prognostic relevance in patients undergoing chemotherapy for recurrent ovarian cancer: a multicenter Italian study. Int J Gynecol Can-cer 7: 78-83, 1997.
65. Geisler JP and Geisler HE: Tumor markers and molecular biological markers in gynecologic malignancies. Curr Opin Obstet Gynecol 13:
31-39, 2001.
66. Gendler SJ: Epithelial mucin genes. Annu Rev Physiol 57: 607-634, 1995.
67. Gonzalez-Martin AJ, Calvo E, Bover I, Rubio MJ, Arcusa A, Casado A, Ojeda B, Balana C, Martinez E, Herrero A, Pardo B, Adrover E, Rifa J, Godes MJ, Moyano A, and Cervantes A: Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive re-current advanced ovarian carcinoma: a GEICO (Grupo Espanol de In-vestigacion en Cancer de Ovario) study. Ann Oncol 16: 749-755, 2005.
68. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, and Lacave AJ:
Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19:
3312-3322, 2001.
69. Griffiths CT: Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 42: 101-104, 1975.
70. Gungor M, Ortac F, Arvas M, Kosebay D, Sonmezer M, and Kose K: The role of secondary cytoreductive surgery for recurrent ovarian cancer.
Gynecol Oncol 97: 74-79, 2005.
71. Hainsworth JD and Greco FA: Etoposide: twenty years later. Ann Oncol 6: 325-341, 1995.
72. Harvey S, Weisman M, O’Dell J, Scott T, Krusemeier M, Visor J, and Swindlehurst C: Chondrex: new marker of joint disease. Clin Chem 44:
509-516, 1998.
73. Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, Ngan HY, and Pecorelli S: Carcinoma of the ovary (FIGO Annual Report). Int J Gynaecol Obstet 83 Suppl 1: 135-166, 2003.
74. Herzog TJ, Holloway RW, and Stuart GC: Workshop: options for ther-apy in ovarian cancer. Gynecol Oncol 90: S45-S50, 2003.
75. Hightower RD, Nguyen HN, Averette HE, Hoskins W, Harrison T, and Steren A: National survey of ovarian carcinoma. IV: Patterns of care and related survival for older patients. Cancer 73: 377-383, 1994.
76. Hogdall CK, Christensen L, and Clemmensen I: The prognostic value of tetranectin immunoreactivity and plasma tetranectin in patients with ovarian cancer. Cancer 72: 2415-2422, 1993.
77. Hogdall CK, Hogdall EV, Hording U, Toftager-Larsen K, Arends J, Nor-gaard-Pedersen B, and Clemmensen I: Use of tetranectin, CA-125 and CASA to predict residual tumor and survival at second- and third-look operations for ovarian cancer. Acta Oncol 35: 63-69, 1996.
78. Hogdall CK, Norgaard-Pedersen B, and Mogensen O: The prognostic value of pre-operative serum tetranectin, CA-125 and a combined index in women with primary ovarian cancer. Anticancer Res 22: 1765-1768, 2002.
79. Holm HH, Gammelgaard J, Jensen F, Smith EH, and Hillman BJ: Ultra-sound in the diagnosis of a palpable abdominal mass. A prospective study of 107 patients. Gastrointest Radiol 7: 149-151, 1982.
80. Holm HH and Skjoldbye B: Interventional ultrasound. Ultrasound Med Biol 22: 773-789, 1996.
81. Hoskins P, Tu D, James K, Pater J, and Koski B: Factors predictive of sur-vival after first relapse or progression in advanced epithelial ovarian car-cinoma: a prediction tree analysis- derived model with test and validation groups. Gynecol Oncol 70: 224-230, 1998.
82. Hunter RW, Alexander ND, and Soutter WP: Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis? Am J Obstet Gynecol 166: 504-511, 1992.
83. Ind T, Iles R, Shepherd J, and Chard T: Serum concentrations of cancer antigen 125, placental alkaline phosphatase, cancer-associated serum antigen and free beta human chorionic gonadotrophin as prognostic markers for epithelial ovarian cancer. Br J Obstet Gynaecol 104: 1024-1029, 1997.
84. Janicke F, Holscher M, Kuhn W, von Hugo R, Pache L, Siewert JR, and Graeff H: Radical surgical procedure improves survival time in patients with recurrent ovarian cancer. Cancer 70: 2129-2136, 1992.
85. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, and Thun MJ: Cancer statistics, 2004. CA Cancer J Clin 54: 8-29, 2004.
86. Johansen JS, Williamson MK, Rice JS, and Price PA: Identification of proteins secreted by human osteoblastic cells in culture. J Bone Miner Res 7: 501-512, 1992.
87. Johnson JR, Williams G, and Pazdur R: End points and United States Food and Drug Administration approval of oncology drugs. J Clin On-col 21: 1404-1411, 2003.
88. Kabawat SE, Bast RC, Jr., Bhan AK, Welch WR, Knapp RC, and Colvin RB: Tissue distribution of a coelomic-epithelium-related antigen recog-nized by the monoclonal antibody OC125. Int J Gynecol Pathol 2: 275-285, 1983.
89. Kaye SB: Chemotherapy for recurrent ovarian cancer. Lancet 361: 2094-2095, 2003.
90. Kierkegaard O, Mogensen O, Mogensen B, and Jakobsen A: Predictive and prognostic values of cancer-associated serum antigen (CASA) and cancer antigen 125 (CA 125) levels prior to second-look laparotomy for ovarian cancer. Gynecol Oncol 59: 251-254, 1995.
91. Kuhn W, Schmalfeldt B, Pache L, Spathe K, Ulm K, Renziehausen K, Noschel H, Canzler E, Richter B, Kroner M, Tilch G, Janicke F, and Graeff H: Disease-adapted relapse therapy for ovarian cancer: results of a prospective study. Int J Oncol 13: 57-63, 1998.
92. Kurtz AB, Tsimikas JV, Tempany CM, Hamper UM, Arger PH, Bree RL, Wechsler RJ, Francis IR, Kuhlman JE, Siegelman ES, Mitchell DG, Sil-verman SG, Brown DL, Sheth S, Coleman BG, Ellis JH, Kurman RJ, Caudry DJ, and McNeil BJ: Diagnosis and staging of ovarian cancer:
comparative values of Doppler and conventional US, CT, and MR imag-ing correlated with surgery and histopathologic analysis--report of the Radiology Diagnostic Oncology Group. Radiology 212: 19-27, 1999.
93. Lichtman SM, Zaheer W, Gal D, Lovecchio J, DeMarco LC, Schulman P, Budman DR, Taibbi R, Fenton C, and Vinciguerra V: No increased risk of Taxol toxicity in older patients. J Am Geriatr Soc 44: 472-474, 1996.
94. Lipschitz DA: Age-related declines in hematopoietic reserve capacity.
Semin Oncol 22: 3-5, 1995.
95. Maggino T and Gadducci A: Serum markers as prognostic factors in epithelial ovarian cancer: an overview. Eur J Gynaecol Oncol 21: 64-69, 2000.
96. Makar AP, Kisic J, and Trope CG: Controversies in surgical management of advanced ovarian cancer (stage III-IV). Eur J Gynaecol Oncol 21:
449-460, 2000.
97. Makar AP, Kristensen GB, Bormer OP, and Trope CG: Is serum CA 125 at the time of relapse a prognostic indicator for further survival progno-sis in patients with ovarian cancer? Gynecol Oncol 49: 3-7, 1993.
98. Malinda KM, Ponce L, Kleinman HK, Shackelton LM, and Millis AJ:
Gp38k, a protein synthesized by vascular smooth muscle cells, stimu-lates directional migration of human umbilical vein endothelial cells.
Exp Cell Res 250: 168-173, 1999.
99. Markman M: Clinical response versus clinical benefit in oncology: not necessarily equivalent terms. J Cancer Res Clin Oncol 123: 363-364, 1997.
100. Markman M: Second-line therapy for potentially platinum-sensitive re-current ovarian cancer: what is optimal treatment? Gynecol Oncol 81:
1-2, 2001.
101. Markman M: Why study third-, fourth-, fifth-, ... line chemotherapy of ovarian cancer? Gynecol Oncol 83: 449-450, 2001.
102. Markman M: The myth of measurable disease is ovarian cancer. J Clin Oncol 21: 3013-3015, 2003.
103. Markman M and Hoskins W: Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population [editorial; comment]. J Clin Oncol 10: 513-514, 1992.
104. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, and Lewis JL, Jr.: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9: 389-393, 1991.
105. Mazurek A, Niklinski J, Laudanski T, and Pluygers E: Clinical tumour markers in ovarian cancer. Eur J Cancer Prev 7: 23-35, 1998.
106. McGuckin MA, Layton GT, Bailey MJ, Hurst T, Khoo SK, and Ward BG:
Evaluation of two new assays for tumor-associated antigens, CASA and OSA, found in the serum of patients with epithelial ovarian carcinoma-- comparison with CA125. Gynecol Oncol 37: 165carcinoma--171, 1990.
107. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, and Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1-6, 1996.
108. Meyer T, Nelstrop AE, Mahmoudi M, and Rustin GJ: Weekly cisplatin
108. Meyer T, Nelstrop AE, Mahmoudi M, and Rustin GJ: Weekly cisplatin